article thumbnail

FDA $7bn plans for 2024: disclose contract manufacturers, restart Cancer Moonshot

Pharmaceutical Technology

This will be spent on oncology clinical trials with underrepresented subgroups, decentralised trials and real-world evidence, and FDA collaboration with foreign regulators. Restarting Cancer Moonshot: +$48m, for a total of $50m for President Biden’s pet project. Source: FDA © GlobalData

article thumbnail

Contract manufacturing issue holds up Regenxbio’s Duchenne gene therapy trial

BioPharma Reporter

Regenxbio says it is to delay dosing of patients in its DMD gene therapy clinical trial following a quality issue at an unnamed third-party contract manufacturer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues

BioSpace

Eli Lilly’s Biologic License Application for its monoclonal antibody lebrikizumab was denied by the regulator after issues were found at a third-party contract manufacturing organization.

article thumbnail

Torbay Pharma: 'We are all about making sterile supply simple'

BioPharma Reporter

Torbay Pharmaceuticals is a sterile injectable contract manufacturer and licence holder based in Devon, UK. We spoke with CEO Emma Rooth about the company's heritage and how it is striving to support the U.S.

article thumbnail

Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production

The Pharma Data

Lipidor has already cooperated with the contract manufacturer Aurena Laboratories regarding hand and skin disinfection sprays and veterinary care products. This disclosure contains information that Lipidor is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).

article thumbnail

Long lead times: Demand currently outstrips supply for contract manufacturing

BioPharma Reporter

As capital project delivery ramps back up to pre-pandemic levels over the coming months and years, the smaller biopharma players are looking outside their own resources for strategic manufacturing and research support, confirms a new market outlook from CRB.

article thumbnail

Samsung Biologics extends Bristol Myers Squibb manufacturing pact

BioPharma Reporter

The big pharma company Bristol Myers Squibb (BMS) has recruited contract manufacturing and development organization (CDMO) Samsung Biologics to manufacture a commercial antibody cancer treatment until 2030.